N-Acetyl Cysteine (NAC) for Mental Clarity
NAC has psychiatric evidence in compulsive and addictive disorders but no credible evidence for improving cognition or focus in healthy people.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not established; psychiatric trials of NAC used 2,000-3,000 mg/day for 8-24 weeks, with no cognitive or clarity endpoint showing benefit in healthy people
- Expected timeframe
- Not established
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. NAC has been studied extensively in psychiatry at 2,000-3,000 mg/day - in trichotillomania, obsessive-compulsive disorder, addiction and as adjunct in bipolar depression and schizophrenia - through effects on glutamate transmission via the cystine-glutamate antiporter and on oxidative stress. None of these trials measured mental clarity, and none supports a nootropic effect in healthy people. Cognitive outcomes in the schizophrenia adjunct trials have been inconsistent and, where positive, apply to a population with baseline cognitive impairment. There is no controlled evidence that NAC sharpens thinking, improves focus or reduces brain fog in people without a psychiatric or oxidative-stress condition.
- titration
- Not applicable
- starting dose
- Not applicable as an established treatment
Evidence
What the studies say
N-Acetylcysteine in Psychiatry: Current Therapeutic Evidence and Potential Mechanisms
Berk M, Malhi GS, Gray LJ +1 more
N-acetylcysteine shows therapeutic promise across several psychiatric disorders through glutamatergic and antioxidant mechanisms.
N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis
Duailibi MS, Cordeiro Q, Brietzke E +4 more
N-acetylcysteine significantly reduced craving symptoms compared with placebo across substance use disorders.
Safety
Caveats
Persistent brain fog usually has a findable cause: sleep deprivation, obstructive sleep apnoea, depression, anxiety, anaemia, B12 deficiency, hypothyroidism, poorly controlled diabetes, perimenopause, medication side effects, alcohol, or post-viral syndromes. Testing is more productive than supplementing. New or progressive cognitive decline affecting daily function needs medical assessment. Safety of NAC: nausea, vomiting, diarrhoea and a sulfurous odour are common, and the psychiatric trial doses of 2,000-3,000 mg/day are considerably higher than typical supplement doses with correspondingly more gastrointestinal intolerance. Rash and rare anaphylactoid reactions occur. Long-term oral safety above 1,800 mg/day is not well characterised. NAC has antiplatelet activity and potentiates nitroglycerin, producing severe headache and hypotension; use caution with anticoagulants and antiplatelet drugs and stop before surgery. Caution in asthma, where bronchospasm has been reported, and in a history of cystine kidney stones. If you take psychiatric medication, discuss NAC with your prescriber rather than adding it independently. Avoid in pregnancy and breastfeeding outside supervised medical use. Regulatory status varies by country.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.